Health Care Knowledge

Introduction Semaglutide, a breakthrough medication in the field of diabetes management, has garnered significant attention in India due to its promising results and potential benefits for patients with type 2 diabetes. This article aims to provide an overview of semaglutide, including its indications, possible side effects, and pricing in the Indian market. Indications Semaglutide belongs to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It is indicated as an add-on to exercise and diet to enhance glycemic control in adults suffering from  type 2 diabetes mellitus . The medication improves blood sugar control by increasing insulin release, decreasing glucagon secretion, and delaying gastric emptying. Side Effects Semaglutide  offers significant benefits for diabetes management, but it's essential to be aware of potential side effects. These can include: Nausea Vomiting Diarrhea Abdominal pain Constipation Weight loss These side effects are

Nitisinone received approval from both the US Food and Drug Administration (FDA) and the EU Agency in January 2002 and February 2005, respectively, for the treatment of patients with Hereditary Tyrosinemia type 1 (HT-1). Nitisinone can also be prescribed for the treatment of alkaptonuria (AKU) in adults.  The drug Nitisinone is currently formulated in dosage strengths of 2 mg, 5 mg, 10 mg, and 20 mg for oral use. Therapy should be administered as quickly as the diagnosis of HT-1 is confirmed. The recommended starting dose is 0.5 mg/kg twice daily. The highest approved oral dose is 2 mg/kg, administered orally twice daily. The capsule is administered either a couple of hours after meals or at least an hour prior to eating. This medicinal product must be administered with dietary restrictions of tyrosine and phenylalanine.  Nitisinone Availability and Sourcing Process: The medication Nitisinone is available in India. It is supplied both as a branded and generic version of the drug. Caps

Introduction Nitisinone is an inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, used to treat  hereditary tyrosinemia type 1  (HT-1). While it is an effective treatment, it comes with specific warnings and precautions that need to be considered to ensure patient safety and efficacy. Elevated Plasma Tyrosine Levels Nitisinone treatment may lead to elevated plasma tyrosine levels due to its inhibition of 4-hydroxyphenyl-pyruvate dioxygenase. To mitigate this risk, it is crucial to maintain a concomitant reduction in dietary tyrosine and phenylalanine. One should keep plasma tyrosine levels below 500 micromol/L to avoid adverse effects. One notable adverse effect of increased plasma tyrosine levels is the development of ocular symptoms, including corneal ulcers, opacities, and photophobia. Regular ophthalmologic examinations, especially slit-lamp examinations, should be performed before initiating Nitisinone treatment. If patients develop eye-related symptoms during treatment, immediate

A drug called Semaglutide, which is sold under different brand names, was approved in 2017 to treat type 2 diabetes (T2D) and in 2021 (under a different brand name) for weight loss. This Type 2 diabetes medicine has become widely popular because of one of its side effects: weight loss.  Both the buzz and surge in demand for semaglutide have created a shortage of the medicine, according to the U.S. FDA, which is expected to remain the same for several months, causing alarm among those with diabetes who rely on  Semaglutide  to help manage their blood sugar level.  The non-diabetic individuals who are seeking slimmer waistlines are responsible for driving this growing demand. Experts caution that it’s crucial to understand Semaglutide is not a miracle medicine—and that there are risks to using the medicine outside of its intended use. Endocrinologist Gregory Dodell, based in Central Park Endocrinology, stated that I`ve noticed an increase in Semaglutide inquiries from individuals. Dr Dod

  The oral semaglutide is approved by the US FDA and other medical authorities around the world along with diet and exercise for controlling body weight and treating Type 2 Diabetes (T2D). The Semaglutide tablets are widely supplied in 3 mg, 7 mg, and 14 mg oral tablet formulas.    Semaglutide tablets are typically less effective than the injectable form, but adding it with basal insulin could boost its effectiveness greater than the injection in terms of treating Type-2 Diabetes (T2D). The combination of semaglutide oral tablets and basal insulin also reveals identical tolerability in users like the injection.   The reason being the oral form of Semaglutide is associated with notable adverse reactions i.e. diarrhea, nausea, and stomach cramps that are specifically digestive tract related. The occurrence of vomiting with an oral semaglutide tablets 14 mg dose is relatively less in comparison with the Dulaglutide 1.5 mg once-weekly dose which is another anti-obesity medicine.   Semagl

  Overview of Oncaspar: Oncaspar is a U.S. Food and Drug Administration (FDA) approved prescription medication to treat acute lymphoblastic leukemia (ALL). The medicine Oncaspar is often used as a part of a chemo regimen. It may also be referred to by its generic name, pegaspargase. Oncaspar injection  is the modified version of an enzyme known as asparaginase. An enzyme basically is a molecule that is designed to accelerate a chemical reaction. Leukemia cells need an amino acid known as asparagine to sustain and replicate. This drug breaks down asparagine into a couple of other substances. Oncaspar is designed to work by scaling down the level of asparagine available to leukemia cells, leading to their destruction. The recommended dosage of  Pegaspargase injection  (Oncaspar) is administered by intravenous (IV) or intramuscular (IM) injection. Oncaspar  (pegaspargase)  in India: If Oncaspar (pegaspargase)- a brand name medication is not approved or not registered in any particular cou